Last $3.20 USD
Change Today 0.00 / 0.00%
Volume 1.0M
As of 8:10 PM 04/17/14 All times are local (Market data is delayed by at least 15 minutes).

rigel pharmaceuticals inc (RIGL) Snapshot

Open
$3.19
Previous Close
$3.20
Day High
$3.47
Day Low
$3.13
52 Week High
03/17/14 - $5.00
52 Week Low
12/18/13 - $2.31
Market Cap
280.1M
Average Volume 10 Days
1.0M
EPS TTM
$-0.99
Shares Outstanding
87.5M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for RIGEL PHARMACEUTICALS INC (RIGL)

rigel pharmaceuticals inc (RIGL) Related Businessweek News

No Related Businessweek News Found

rigel pharmaceuticals inc (RIGL) Details

Rigel Pharmaceuticals, Inc., a clinical-stage drug development company, discovers and develops novel, small-molecule drugs for the treatment of inflammatory and autoimmune diseases, as well as muscle disorders. Its product development programs include fostamatinib, an oral spleen tyrosine kinase (SYK) inhibitor that intends to enter Phase III clinical trials for immune thrombocytopenic purpura and a Phase II clinical trial for immunoglobulin A nephropathy; R348, a topical janus kinase/SYK inhibitor in Phase II clinical trials for the treatment of keratoconjunctivitis sicca or chronic dry eye; R118, an adenosine monophosphate-activated protein kinase activator that intends to enter Phase I clinical trial; and two oncology product candidates in Phase I development. It also has small molecule discovery programs in muscle wasting. Rigel Pharmaceuticals, Inc. has collaboration agreement Daiichi Sankyo to pursue research related to a specific target from a class of drug targets called ligases that control cancer cell proliferation through protein degradation; and a license agreement with BerGenBio AS for the development and commercialization of an oncology program. The company was founded in 1996 and is based in South San Francisco, California.

129 Employees
Last Reported Date: 03/4/14
Founded in 1996

rigel pharmaceuticals inc (RIGL) Top Compensated Officers

Chairman, Chief Executive Officer and Member ...
Total Annual Compensation: $695.1K
President and Chief Operating Officer
Total Annual Compensation: $551.7K
Co-Founder, Executive Vice President, Directo...
Total Annual Compensation: $559.6K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $441.3K
Chief Medical Officer and Executive Vice Pres...
Total Annual Compensation: $521.3K
Compensation as of Fiscal Year 2013.

rigel pharmaceuticals inc (RIGL) Key Developments

Rigel Pharmaceuticals, Inc. Announces Resignation of Hollings C. Renton as Member of the Board of Directors, Effective March 30, 2014

On March 17, 2014, Hollings C. Renton notified Rigel Pharmaceuticals, Inc. of his decision to resign as a member of the Board of Directors of the company, effective March 30, 2014. At the time of Mr. Renton’s resignation, he was an independent director and member of the Audit Committee of the Board.

Rigel Pharmaceuticals, Inc. Reports Unaudited Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2013

Rigel Pharmaceuticals, Inc. reported unaudited earnings results for the fourth quarter and full year ended December 31, 2013. For the fourth quarter of 2013, Rigel reported a net loss of $16.9 million or $0.19 basic and diluted per share compared to a net loss of $25.5 million or $0.30 basic and diluted per share in the fourth quarter of 2012. Contract revenues were $5.750 million. Loss from operations was $16.944 million against $25.616 million a year ago. For the twelve months ended December 31, 2013, Rigel reported contract revenue of $7.2 million and a net loss of $89.0 million or $1.02 basic and diluted per share compared to contract revenue of $2.3 million and a net loss of $98.8 million or $1.32 per basic and diluted share in 2012. Loss from operations was $89.469 million against $99.377 million a year ago.

Rigel Pharmaceuticals, Inc. Presents at 26th Annual ROTH Conference, Mar-11-2014 02:00 PM

Rigel Pharmaceuticals, Inc. Presents at 26th Annual ROTH Conference, Mar-11-2014 02:00 PM. Venue: The Ritz Carlton, 1 Ritz Carlton Dr, Dana Point, CA 92629, United States. Speakers: James M. Gower, Chairman, Chief Executive Officer and Member of Finance Committee.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
RIGL:US $3.20 USD 0.00

RIGL Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Arqule Inc $1.66 USD -0.05
Cell Therapeutics Inc $3.07 USD +0.08
CrystalGenomics Inc 13,400 KRW +200.00
Progenics Pharmaceuticals Inc $3.50 USD -0.06
Wyeth Ltd 844.85 INR 0.00
View Industry Companies
 

Industry Analysis

RIGL

Industry Average

Valuation RIGL Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 39.1x
Price/Book 1.3x
Price/Cash Flow NM Not Meaningful
TEV/Sales 9.5x
 | 

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact RIGEL PHARMACEUTICALS INC, please visit www.rigel.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.